NetworkNewsBreaks – IGC Pharma Inc. (NYSE Americ
Post# of 430
(Total Views: 191)
Posted On: 08/02/2023 4:33:56 PM
NetworkNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Expands Phase 2 Trial to Add New Site
IGC Pharma (NYSE American: IGC) today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of its ongoing phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease. According to clinicaltrials.gov, IGC-AD1 is the only natural THC-based investigational drug undergoing FDA trials. The therapy relies on low doses of THC and another compound as pharmaceutical active agents for the treatment of Alzheimer’s and, in pre-clinical and phase 1 studies, has shown the potential to be effective in ameliorating Aβ plaques and to reduce neuropsychiatric symptoms such as agitation in dementia due to Alzheimer’s. “We are excited to announce our partnership with the University of Puerto Rico, a remarkable institution conducting world-leading medical research,” said Ram Mukunda, CEO of IGC Pharma. “The addition of this site with individuals living with Alzheimer’s from the Hispanic community is a significant milestone in our phase 2 trial. Alzheimer’s disease, including the resulting symptom of agitation, is complex to treat and incredibly hard to live with.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
IGC Pharma (NYSE American: IGC) today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of its ongoing phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease. According to clinicaltrials.gov, IGC-AD1 is the only natural THC-based investigational drug undergoing FDA trials. The therapy relies on low doses of THC and another compound as pharmaceutical active agents for the treatment of Alzheimer’s and, in pre-clinical and phase 1 studies, has shown the potential to be effective in ameliorating Aβ plaques and to reduce neuropsychiatric symptoms such as agitation in dementia due to Alzheimer’s. “We are excited to announce our partnership with the University of Puerto Rico, a remarkable institution conducting world-leading medical research,” said Ram Mukunda, CEO of IGC Pharma. “The addition of this site with individuals living with Alzheimer’s from the Hispanic community is a significant milestone in our phase 2 trial. Alzheimer’s disease, including the resulting symptom of agitation, is complex to treat and incredibly hard to live with.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)IGC Pharma Inc. (IGC) Stock Research Links
Scroll down for more posts ▼